Neutralizing recombinant human chimeric antibody recognizing human IL-17A. This antibody has not been tested for crossreactivity with other species.

IL-17, IL17, Interleukin-17A, CTLA8, Cytotoxic T-Lymphocyte-Associated Antigen 8

Antibody was added at various concentrations using the IL- 17RA[Biotin]:IL-17A Inhibitor Screening binding assay (BPS Cat. #72060). Assay was performed according to the recommended protocol.

8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

Purified using protein A affinity chromatography from HEK293 supernatants.

Aqueous buffer solution

Stable for at least 12 months at -80°C.

Useful for binding studies and for the inhibition of IL-17RA:IL-17A interactions.

1. Lubberts, E., et al., Arthritis Rheum. 2004; 50(2): 650-659.
2. Cheng, X., et al., Atherosclerosis. 2011; 215(2): 471-474.

Avoid freeze/thaw cycles. Store diluted antibody with carrier protein (BSA 0.1 – 0.5%) at 4°C, stable for 2 weeks.

Immunotherapy

Antibody